H.C. Wainwright raised the firm’s price target on Cabaletta Bio to $30 from $25 and keeps a Buy rating on the shares following the Q4 report. The company company has $241.2M in cash and a support runway into the first half of 2026, which is sufficient to support the multiple active new drug applications, the analyst tells investors in a research note. The firm sees a “catalyst-rich” 2024 for Cabaletta.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Receives Orphan Drug Status for CABA-201
- Cabaletta Bio granted Orphan Drug designation to CABA-201
- Cabaletta Bio treatment of systemic sclerosis granted orphan designation
- Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet
